Cargando…

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieira, Raquel, Souto, Selma B., Sánchez-López, Elena, López Machado, Ana, Severino, Patricia, Jose, Sajan, Santini, Antonello, Fortuna, Ana, García, Maria Luisa, Silva, Amelia M., Souto, Eliana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958392/
https://www.ncbi.nlm.nih.gov/pubmed/31658729
http://dx.doi.org/10.3390/ph12040152
_version_ 1783487403113054208
author Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
López Machado, Ana
Severino, Patricia
Jose, Sajan
Santini, Antonello
Fortuna, Ana
García, Maria Luisa
Silva, Amelia M.
Souto, Eliana B.
author_facet Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
López Machado, Ana
Severino, Patricia
Jose, Sajan
Santini, Antonello
Fortuna, Ana
García, Maria Luisa
Silva, Amelia M.
Souto, Eliana B.
author_sort Vieira, Raquel
collection PubMed
description Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.
format Online
Article
Text
id pubmed-6958392
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69583922020-01-23 Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I Vieira, Raquel Souto, Selma B. Sánchez-López, Elena López Machado, Ana Severino, Patricia Jose, Sajan Santini, Antonello Fortuna, Ana García, Maria Luisa Silva, Amelia M. Souto, Eliana B. Pharmaceuticals (Basel) Review Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed. MDPI 2019-10-10 /pmc/articles/PMC6958392/ /pubmed/31658729 http://dx.doi.org/10.3390/ph12040152 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vieira, Raquel
Souto, Selma B.
Sánchez-López, Elena
López Machado, Ana
Severino, Patricia
Jose, Sajan
Santini, Antonello
Fortuna, Ana
García, Maria Luisa
Silva, Amelia M.
Souto, Eliana B.
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
title Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
title_full Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
title_fullStr Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
title_full_unstemmed Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
title_short Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
title_sort sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—review of classical and new compounds: part-i
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958392/
https://www.ncbi.nlm.nih.gov/pubmed/31658729
http://dx.doi.org/10.3390/ph12040152
work_keys_str_mv AT vieiraraquel sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT soutoselmab sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT sanchezlopezelena sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT lopezmachadoana sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT severinopatricia sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT josesajan sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT santiniantonello sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT fortunaana sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT garciamarialuisa sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT silvaameliam sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti
AT soutoelianab sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti